Abstract

Objective To study the clinical and pathologic features, diagnosis, treatment and prognosis of splenic marginal zone lymphoma (SMZL). Methods We reported the detailed clinical and pathologic presentation of a patient with SMZL, and monitored fellow-up to 16 years. Results Patients present with splenomegaly. SMZL usually involve bone marrow, peripheral blood and hilar splenic lympha nodes. Peripheral lymph nodes and nonhematolymphoid organs can be involved as well, but to a lesser extent.Microscopically, tumor cells are small to medium in size, with dispersed chromation. Tumor cells are slgM(+),CD+20, CD+79a,, bcl-2(+), CD-3, CD-5, CD-10, CD-23 and CyclinDl(-). Conclusion SMZL is a rare low-grade B-cell lymphoma with an indolent clinical course. Spleneetomy and chemotherapy are effective treatment but SMZL cannot be completely cured and may transform to large B-cell lymphoma at last. Key words: Lymphoma; Spleen; Pathology, clinical; Immunohistochemistry; Therapy; Prognosis

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.